Novartis has provided updated data from phase 3 trials of ZOLGENSMA (onasemnogene abeparvovec-xioi) for patients with spinal muscular atrophy. …
Latest Video
New Stories
-
Biogen appoints senior leader as new managing director
January 22, 2020 - - Latest News -
New leadership for the Department of Health
January 22, 2020 - -
AusBiotech opens 2020 CEO Industry Position Survey
January 22, 2020 - - Latest News -
PHARMAC protest: Couple tow coffin across NZ
January 22, 2020 - - Latest News -
Lundbeck makes global climate change A-list
January 22, 2020 - - Latest News -
PBAC Executive: It meets when it meets
January 22, 2020 - - Latest News -
Guild rejects hospital call for extended dispensing powers
January 21, 2020 - - Latest News